# Study of Intravenous COVI-MSC for Treatment of COVID-19-Induced Acute Respiratory Distress

> **NCT04903327** · PHASE2 · TERMINATED · sponsor: **Sorrento Therapeutics, Inc.** · enrollment: 43 (actual)

## Conditions studied

- Covid19

## Interventions

- **BIOLOGICAL:** COVI-MSC
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04903327
- **Lead sponsor:** Sorrento Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-11-16
- **Primary completion:** 2022-08-29
- **Final completion:** 2022-11-23
- **Target enrollment:** 43 (ACTUAL)
- **Why stopped:** Due to considerably slow enrollment, unable to reach enrollment targets
- **Last updated:** 2023-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04903327

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04903327, "Study of Intravenous COVI-MSC for Treatment of COVID-19-Induced Acute Respiratory Distress". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04903327. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*